TL
Therapeutic Areas
Vivani Medical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| NPM-139 | Chronic Weight Management (Obesity/Overweight) | Phase 1 |
| NPM-133 | Type 2 Diabetes | Preclinical |
| NPM-115 | Type 2 Diabetes (proof-of-concept) | Phase 1 Completed |
| NanoPortal Platform - Veterinary | Canine and Feline Cardiometabolic Disorders | Research |
| Orion System (Cortigent) | Artificial Vision & Stroke Rehabilitation | Early Feasibility |
Leadership Team at Vivani Medical
AM
Adam Mendelsohn, Ph.D.
Co-Founder & Chief Executive Officer
LP
Lisa Porter, M.D.
Chief Medical Officer
AB
Anthony Baldor, M.S., M.B.A.
Chief Financial Officer
DD
Don Dwyer, M.B.A.
Chief Business Officer
GW
Gregg Williams
Director & Chairman of the Board
AM
Aaron Mendelsohn, J.D.
Director
DB
Dean Baker, Ph.D.
Director
DB
Daniel Bradbury
Director
AL
Alexandra L. Popoff (formerly Larson), J.D., M.B.A.
Director
AV
Andrew Vick, Ph.D.
Advisor